Get ready for a game-changer in gastric cancer treatment! Laparoscopic Distal Gastrectomy (LDG) is a promising alternative to open surgery for T4a gastric cancer patients.
In a groundbreaking study published in JAMA Surgery, researchers compared the short-term outcomes of LDG and open distal gastrectomy (ODG) for clinical T4a gastric cancer. The results? Astonishingly similar!
At 30 days post-surgery, the morbidity rates were nearly identical: 22.1% for LDG and 21.2% for ODG. Most complications were minor, and major complications occurred in less than 4% of cases for both procedures.
But here's where it gets controversial: the study found no significant differences in surgical and general complications between the two groups. Even the mortality rate at 30 days was comparable, with only a 1% difference between LDG and ODG.
And this is the part most people miss: the median comprehensive complication index scores, which measure the severity of postoperative complications, were lower in the LDG group (12.2) compared to ODG (20.9).
Lead author Tran Quang Dat, MD, MSc, and his team concluded that LDG is not only feasible and safe for serosa-invasive gastric cancer but also has the potential to be an alternative treatment for cT4a gastric cancer when performed by qualified surgeons.
The UMC-UPPERGI-01 trial, a single-center, open-label study, randomly assigned 240 patients with cT4a gastric cancer to either LDG or ODG. Both groups underwent distal gastrectomy with D2 lymphadenectomy, but the LDG group had a total laparoscopic approach, ensuring consistency and surgical quality.
The primary endpoints of the trial were 3-year overall survival and relapse-free survival, with secondary endpoints including operative morbidity, time, and lymph node resection.
Eligible patients were aged 18-80 with pathologically confirmed gastric adenocarcinoma located in the middle or lower stomach. Most patients in both groups were male, with similar ASA-PS and ECOG performance status.
Data analysis revealed no significant differences in intraoperative complications between LDG and ODG, and the use of LDG did not independently predict postoperative morbidity.
The presence of a comorbidity was the only factor independently correlated with the risk of postoperative complications.
This study fills a critical evidence gap and supports the potential of LDG as a curative treatment for T4a gastric cancer. However, the ongoing follow-up of this trial will determine if LDG is non-inferior to ODG regarding oncological survival.
So, is laparoscopic distal gastrectomy the future of gastric cancer treatment? What are your thoughts on this innovative approach? Share your insights and let's spark a discussion!
